Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a median age of 65 years (range, 38—79 years). The med...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/676 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024442521976832 |
|---|---|
| author | S. S. Bessmeltsev L. V. Stelmashenko E. I. Podoltseva E. V. Kariagina G. N. Salogub А. S. Nisamutdinova L. M. Matuhina K. M. Abdulkadyrov |
| author_facet | S. S. Bessmeltsev L. V. Stelmashenko E. I. Podoltseva E. V. Kariagina G. N. Salogub А. S. Nisamutdinova L. M. Matuhina K. M. Abdulkadyrov |
| author_sort | S. S. Bessmeltsev |
| collection | DOAJ |
| description | Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a median age of 65 years (range, 38—79 years). The median number of previous treatments was 3 (range, 1-9). For patients who received bortezomib plus dexamethasone the overall response rate was 73%. 38% patients achieved CR. CR in patients receiving bortezomib plus dexamethasone earlier vs later (≤ 3 и ≥ 4 line chemotherapy) were: 48% vs 27,5%. Bortezomib is active in patients with relapsed MM, including elderly patients. Side effects were predictable and manageable; principal toxicities were hematological, gastrointestinal, and peripheral neuropathy. The most common adverse events reported were asthenia (52%), neuropathy (53%), thrombocytopenia (32%), anemia (30%). Neuropathy greater than grade 2 was more frequent in patients who received 3 or more prior therapy regimens. |
| format | Article |
| id | doaj-art-8553a7bdc296417c8a2e1b3fa806ced5 |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-8553a7bdc296417c8a2e1b3fa806ced52025-08-20T03:01:06ZrusABV-pressОнкогематология1818-83462413-40232022-11-0104616610.17650/1818-8346-2007-0-4-61-66554Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myelomaS. S. Bessmeltsev0L. V. Stelmashenko1E. I. Podoltseva2E. V. Kariagina3G. N. Salogub4А. S. Nisamutdinova5L. M. Matuhina6K. M. Abdulkadyrov7Russian Research Institute of Hematology and TransfusiologyRussian Research Institute of Hematology and TransfusiologyCity Hospital 31City Hospital 15St. Petersburg State Pavlov Medical UniversityAlexandrovsky HospitalRoad Clinic HospitalRussian Research Institute of Hematology and TransfusiologyTheproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a median age of 65 years (range, 38—79 years). The median number of previous treatments was 3 (range, 1-9). For patients who received bortezomib plus dexamethasone the overall response rate was 73%. 38% patients achieved CR. CR in patients receiving bortezomib plus dexamethasone earlier vs later (≤ 3 и ≥ 4 line chemotherapy) were: 48% vs 27,5%. Bortezomib is active in patients with relapsed MM, including elderly patients. Side effects were predictable and manageable; principal toxicities were hematological, gastrointestinal, and peripheral neuropathy. The most common adverse events reported were asthenia (52%), neuropathy (53%), thrombocytopenia (32%), anemia (30%). Neuropathy greater than grade 2 was more frequent in patients who received 3 or more prior therapy regimens.https://oncohematology.abvpress.ru/ongm/article/view/676bortezomib (velcade)multiple myelomacomplete remissionoverall responseneuropathy |
| spellingShingle | S. S. Bessmeltsev L. V. Stelmashenko E. I. Podoltseva E. V. Kariagina G. N. Salogub А. S. Nisamutdinova L. M. Matuhina K. M. Abdulkadyrov Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma Онкогематология bortezomib (velcade) multiple myeloma complete remission overall response neuropathy |
| title | Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma |
| title_full | Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma |
| title_fullStr | Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma |
| title_full_unstemmed | Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma |
| title_short | Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma |
| title_sort | bortezomib velcade in combination with dexamethasone eor relapsed or refractory myeloma |
| topic | bortezomib (velcade) multiple myeloma complete remission overall response neuropathy |
| url | https://oncohematology.abvpress.ru/ongm/article/view/676 |
| work_keys_str_mv | AT ssbessmeltsev bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma AT lvstelmashenko bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma AT eipodoltseva bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma AT evkariagina bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma AT gnsalogub bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma AT asnisamutdinova bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma AT lmmatuhina bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma AT kmabdulkadyrov bortezomibvelcadeincombinationwithdexamethasoneeorrelapsedorrefractorymyeloma |